A 24-week Evaluation of GSK573719/Vilanterol (125/25mcg) and Components in COPD

NCT01313637 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1493

Enrollment

INDUSTRY

Sponsor class

Conditions

Pulmonary Disease, Chronic Obstructive

Interventions

DRUG: GSK573719/GW642444 125/25mcg
DRUG: GSK573719 125mcg
DRUG: GW642444 25mcg
DRUG: Placebo only

Sponsor

GlaxoSmithKline